Quantcast Biomimetic Therapeutics Receives First Orthopedic Marketing Approval For Augment(TM) - Congoo
 
 
PEOPLE Log In
BioMimetic Therapeutics Receives First Orthopedic Marketing Approval for Augment(TM)
Have an interest in this Story?
Sign Up for Real-Time email updates
Forbes.com  | November 04, 2009

BusinessWire - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment(TM) Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in C...
Read Full Article   
 
Leave a Comment: You must be logged in to leave a comment     Log in | Register
 

Featured Members
Niladri Roy Niladri Roy
Manager-International Marketing
Computer Services
Matthew Clark Matthew Clark
Mentor
Entrepreneur

  
  View more profiles

 
Access dozens of premium and subscriptions sites Free! Download now.

Advertise   |   Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms   |   Privacy   |   Need Help?   |   Site Map
Copyright ©2009 Congoo.com. All Rights Reserved.